{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:31:13Z","timestamp":1790109073681,"version":"4.0.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.beem.2026.102095","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:21:59Z","timestamp":1771359719000},"page":"102095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas"],"prefix":"10.1016","volume":"40","author":[{"given":"Yaron","family":"Rudman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.beem.2026.102095_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI0215912","article-title":"Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms","volume":"110","author":"Schuff","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib5","first-page":"798","article-title":"The cytogenesis and pathogenesis of pituitary adenomas","volume":"19","author":"Asa","year":"1998","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.beem.2026.102095_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41419-019-1526-0","article-title":"Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK\/EGR1 and AKT\/mTOR pathway respectively","volume":"10","author":"Tang","year":"2019","journal-title":"Cell Death Dis"},{"issue":"6__6","key":"10.1016\/j.beem.2026.102095_bib7","article-title":"History of levodopa and dopamine agonists in Parkinson\u2019s disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurology"},{"issue":"8133","key":"10.1016\/j.beem.2026.102095_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(79)90120-X","article-title":"Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy","volume":"314","author":"Wass","year":"1979","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0015-0282(16)60909-3","article-title":"Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration","volume":"52","author":"Melis","year":"1989","journal-title":"Fertil Steril"},{"issue":"14","key":"10.1016\/j.beem.2026.102095_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A Comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic Amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beem.2026.102095_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/07853899809002486","article-title":"Treatment of prolactinomas","volume":"30","author":"Colao","year":"1998","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","article-title":"Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients","volume":"46","author":"Ottenhausen","year":"2023","journal-title":"Neurosurg Rev"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib14","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr Oncol"},{"issue":"12","key":"10.1016\/j.beem.2026.102095_bib15","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","article-title":"First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center","volume":"44","author":"Andereggen","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf025","article-title":"The hypothalamic arcuate nucleus dopaminergic neurons: more than just prolactin secretion","volume":"166","author":"Lim","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2026.102095_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3389\/fendo.2018.00768","article-title":"The mechanism and pathways of dopamine and dopamine agonists in prolactinomas","volume":"9","author":"Liu","year":"2019","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2265.1991.tb00928.x","article-title":"Dopamine, the dopamine D2 receptor and pituitary tumours","volume":"35","author":"Wood","year":"1991","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","journal-title":"ENDO"},{"key":"10.1016\/j.beem.2026.102095_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fendo.2018.00469","article-title":"Dopamine agonists for pituitary adenomas","volume":"9","author":"Cooper","year":"2018","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beem.2026.102095_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2026.102095_bib26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/andr.13428","article-title":"Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men","volume":"11","author":"Rudman","year":"2023","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00431-025-06200-x","article-title":"Hyperprolactinemia in children and adolescents: clinical characteristics and etiological spectrum","volume":"184","author":"Kilci","year":"2025","journal-title":"Eur J Pedia"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis*","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones?","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jcem-51-3-438","article-title":"Rapid regression of pituitary prolactinomas during bromocriptine treatment*","volume":"51","author":"Thorner","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.beem.2026.102095_bib33","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102095_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2026.102095_bib36","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men*","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cen.14541","article-title":"Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: does size really matter?","volume":"95","author":"Rudman","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-025-04215-w","article-title":"Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study","volume":"89","author":"Rudman","year":"2025","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.beem.2026.102095_bib39","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"Dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.beem.2026.102095_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-023-03310-0","article-title":"DRD2 expression based on 18F-fallypride PET\/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study","volume":"80","author":"Tang","year":"2023","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib43","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-018-1702-5","article-title":"Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas","volume":"62","author":"Huang","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib46","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.4158\/EP10369.CR","article-title":"Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas","volume":"17","author":"Iyer","year":"2011","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.beem.2026.102095_bib47","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"ement_1","key":"10.1016\/j.beem.2026.102095_bib48","article-title":"SAT616 differentiating resistant prolactinoma from macroprolactinemia","volume":"7","author":"Lacount","year":"2023","journal-title":"J Endocr Soc"},{"issue":"7","key":"10.1016\/j.beem.2026.102095_bib49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF03343751","article-title":"A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients","volume":"23","author":"De Luis","year":"2000","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102095_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1027905","article-title":"The efficacy and safety of quinagolide in hyperprolactinemia treatment: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2026.102095_bib52","doi-asserted-by":"crossref","first-page":"e4551","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib53","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","article-title":"Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma","volume":"25","author":"Rudman","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102095_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1705300","article-title":"Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery","volume":"16","author":"Prinzi","year":"2025","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh","year":"2015","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.beem.2026.102095_bib56","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","article-title":"Long-term follow-up of 84 patients with giant prolactinomas\u2014a Swedish Nationwide Study","volume":"108","author":"Himonakos","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib57","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/cen.15120","article-title":"Visual morbidity in macroprolactinoma: a retrospective cohort study","volume":"101","author":"Rudman","year":"2024","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2026.102095_bib58","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0161-6420(85)33853-8","article-title":"Visual function in prolactinoma patients treated with Bromocriptine","volume":"92","author":"Moster","year":"1985","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.beem.2026.102095_bib59","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2265.2008.03364.x","article-title":"Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma","volume":"70","author":"Raverot","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4183\/aeb.2023.339","article-title":"Temporal lobe herniation and chiasmopathy during dopamine agonist therapy for prolactinoma","volume":"19","author":"Giraldi","year":"2023","journal-title":"Acta Endocrinol (Buch)"},{"issue":"5","key":"10.1016\/j.beem.2026.102095_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib63","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"Santos-Silva","year":"2011","journal-title":"Obesity"},{"issue":"10","key":"10.1016\/j.beem.2026.102095_bib64","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1530\/EC-19-0286","article-title":"Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis","volume":"8","author":"Byberg","year":"2019","journal-title":"Endocr Connect"},{"issue":"ement_1","key":"10.1016\/j.beem.2026.102095_bib65","article-title":"SAT-082 metabolic effects of prolactin-lowering therapy in prolactinoma: a systematic review and meta-analysis","volume":"9","author":"McQuade","year":"2025","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11102-018-0907-1","article-title":"Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review","volume":"21","author":"\u010ces\u00e1k","year":"2018","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib69","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet","year":"2015","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13494","article-title":"Ischemic stroke risk in patients with dopamine agonist-treated hyperprolactinemia","volume":"37","author":"Akirov","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib71","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib72","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"issue":"6452","key":"10.1016\/j.beem.2026.102095_bib73","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.289.6452.1101","article-title":"Psychotic reactions during treatment of pituitary tumours with dopamine agonists","volume":"289","author":"Turner","year":"1984","journal-title":"Br Med J (Clin Res Ed"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2026.102095_bib77","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib79","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1210\/clinem\/dgad758","article-title":"Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases","volume":"109","author":"Chen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.beem.2026.102095_bib81","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4158\/EP15804.OR","article-title":"Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas","volume":"21","author":"Tirosh","year":"2015","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EJE-21-0561","article-title":"Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline","volume":"185","author":"Biagetti","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib83","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-16-0897","article-title":"MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment","volume":"176","author":"Eroukhmanoff","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2026.102095_bib84","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2026.102095_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1195792","article-title":"Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas","volume":"14","author":"Medina","year":"2023","journal-title":"Front Endocrinol"},{"issue":"21","key":"10.1016\/j.beem.2026.102095_bib86","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib88","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102095_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2015.00011","article-title":"Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile?","volume":"6","author":"Vilar","year":"2015","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib90","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-21-0977","article-title":"Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors","volume":"186","author":"Cozzi","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102095_bib91","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"Glezer","year":"2020","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.beem.2026.102095_bib93","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.15304","article-title":"Safety of cabergoline for prolactinoma in pregnancy: a systematic review and meta-analysis","volume":"103","author":"Chakraborty","year":"2025","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102095_bib94","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-15-0282","article-title":"Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature","volume":"173","author":"Dekkers","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102095_bib96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000495184","article-title":"Giant prolactinomas","volume":"109","author":"Shimon","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2026.102095_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1668255","article-title":"Cystic versus non-cystic prolactinoma: clinical, hormonal, radiological, and remission outcomes in Basrah","volume":"16","author":"Reman","year":"2025","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2026.102095_bib98","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2016-2008","article-title":"Dopamine agonists can reduce cystic prolactinomas","volume":"101","author":"Faje","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib99","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2026.102095_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101711","article-title":"Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists","volume":"36","author":"Chanson","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102095_bib101","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/EJE-20-0125","article-title":"Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma","volume":"183","author":"Allard","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2026.102095_bib102","series-title":"The Pituitary","first-page":"467","article-title":"Prolactinoma","author":"Chanson","year":"2017"},{"issue":"4","key":"10.1016\/j.beem.2026.102095_bib103","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study*","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:35Z","timestamp":1788866315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521690X26000163"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102095","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102095"}}